Immuno-Oncology Drugs Market By Drugs Type (Immune Checkpoint Inhibitors (CTL-4 Checkpoint Inhibitor and PD-1 & PD-L1 Checkpoint Inhibitor), Monoclonal Antibodies, Cytokine Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, By Cancer Type (Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma), Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, Head & Neck Cancers), By Distribution Channel (Retail Pharmacies, Hospitals Pharmacies, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2029

Immuno-oncology drugs are those which use patient’s immune system to fight against different type of cancer. Immuno-oncology drugs uses novel drugs such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy, and cancer vaccines which that boost the immune system of patients and fight against cancer.

 

Increasing rate and incidence of cancer is expected to be a major factor which will boost the demand for immune-oncology drugs for its treatment products in market in upcoming time period. For instance, as per the National Cancer Institute, it was estimated that in 2018 1,735,350 new cases of cancer will be diagnosed in the U.S. and 609,640 people will die from the disease.

Furthermore, increasing launches of new immune-oncology drugs in market by key players is also expected to drive the market growth over forecast period. For instance, in 2017, Merck, Sharpe and Dohme launched its immune-oncology drug Keytruda (pembrolizumab) in India for the treatment of advanced melanoma.

The immuno-oncology drugs market has been segmented on the basis of drug type, cancer type, distribution channel, and region.

The drug type segment includes immune checkpoint inhibitors (CTL-4 Checkpoint Inhibitor, and PD-1 & PD-L1 Checkpoint Inhibitor), Monoclonal Antibodies, Cytokine Based Immunotherapy, Cancer Vaccines, and CAR-T Cell Therapy.

On the basis of cancer type, the immuno-oncology drugs market has been segmented into Non-Small cell lung cancer, acute myeloid leukemia, lymphoma (hodgkin’s and non-hodgkin’s lymphoma), multiple myeloma, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, gastric cancers, glioblastoma, and head & neck cancers.

On the basis of distribution channel, the immuno-oncology drugs market has been segmented in retail pharmacies, hospitals pharmacies, and Other.

On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account major market share as compared to that of other regions.

Key players operating in the immuno-oncology drugs market includes, Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., Gilead Sciences Inc., Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte.

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
   • PORTER’s
   • Investment Outlook
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for Immuno-Oncology Drugs Strategies
     • Key Questions this Study will Answer

     • By Drugs Type (Immune Checkpoint Inhibitors (CTL-4 Checkpoint Inhibitor and PD-1 & PD-L1 Checkpoint Inhibitor), Monoclonal Antibodies, Cytokine Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, By Cancer Type (Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma), Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, Head & Neck Cancers)

       By Distribution Channel (Retail Pharmacies, Hospitals Pharmacies, and Others)

       By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Overview
   • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
   • Y-o-Y Growth Analysis (%), 2020 – 2030
   • Regional Trends
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Regional Analysis
   • Regional Revenue Analysis
   • Regional By segment Analysis
   • Reasons for regional growth
   • Key Player of particular region
   • Countries Include in the report:

1. • • North America (U.S., Canada)
     • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
     • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
     • Latin America (Brazil, Mexico, Rest of Latin America)
     • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
   • Competitive Overview
   • Competitive Benchmarking
   • Market Share Analysis
   • Key Developments In The  Immuno-Oncology Drugs Market
   • Key Developments: Mergers & Acquisitions
   • Key Developments: Collaboration
   • Key Developments: Contracts & Agreements
   • Key Developments: Expansion
   • Key Developments: Product Developments
2. Company Profiles

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies
• SWOT Analysis

• • Amgen, Inc.

  • AstraZeneca Plc

  • Bristol-Myers Squibb

  • Celgene Corporation

  • Eli Lilly and Company

  • Merck & Co.

  • F. Hoffmann-La Roche AG

  • Johnson & Johnson

  • Novartis International AG

  • AbbVie, Inc.

  • Pfizer Inc.

  • Sanofi S.A.

  • Gilead Sciences Inc.

  • Celldex Therapeutics

  • ImmunoCellular Therapeutics

  • Incyte.

1. The Last Word
   • Future Impact
   • About Us
   • Contact